TY - JOUR
T1 - PsyCog
T2 - A computerised mini battery for assessing cognition in psychosis
AU - Gifford, George
AU - Cullen, Alexis E
AU - Vieira, Sandra
AU - Searle, Anja
AU - McCutcheon, Robert A
AU - Modinos, Gemma
AU - Stone, William S
AU - Hird, Emily
AU - Barnett, Jennifer
AU - van Hell, Hendrika H
AU - Catalan, Ana
AU - Millgate, Edward
AU - Taptiklis, Nick
AU - Cormack, Francesca
AU - Slot, Margot E
AU - Dazzan, Paola
AU - Maat, Arija
AU - de Haan, Lieuwe
AU - Facorro, Benedicto Crespo
AU - Glenthøj, Birte
AU - Lawrie, Stephen M
AU - McDonald, Colm
AU - Gruber, Oliver
AU - van Amelsvoort, Thérèse
AU - Arango, Celso
AU - Kircher, Tilo
AU - Nelson, Barnaby
AU - Galderisi, Silvana
AU - Bressan, Rodrigo A
AU - Kwon, Jun Soo
AU - Weiser, Mark
AU - Mizrahi, Romina
AU - Sachs, Gabriele
AU - Kirschner, Matthias
AU - Reichenberg, Abraham
AU - Kahn, René
AU - McGuire, Philip
AU - PSYSCAN Consortium
N1 - © 2024 Published by Elsevier Inc.
PY - 2024/9
Y1 - 2024/9
N2 - Despite the functional impact of cognitive deficit in people with psychosis, objective cognitive assessment is not typically part of routine clinical care. This is partly due to the length of traditional assessments and the need for a highly trained administrator. Brief, automated computerised assessments could help to address this issue. We present data from an evaluation of PsyCog, a computerised, non-verbal, mini battery of cognitive tests. Healthy Control (HC) (N = 135), Clinical High Risk (CHR) (N = 233), and First Episode Psychosis (FEP) (N = 301) participants from a multi-centre prospective study were assessed at baseline, 6 months, and 12 months. PsyCog was used to assess cognitive performance at baseline and at up to two follow-up timepoints. Mean total testing time was 35.95 min (SD = 2.87). Relative to HCs, effect sizes of performance impairments were medium to large in FEP patients (composite score G = 1.21, subtest range = 0.52-0.88) and small to medium in CHR patients (composite score G = 0.59, subtest range = 0.18-0.49). Site effects were minimal, and test-retest reliability of the PsyCog composite was good (ICC = 0.82-0.89), though some practice effects and differences in data completion between groups were found. The present implementation of PsyCog shows it to be a useful tool for assessing cognitive function in people with psychosis. Computerised cognitive assessments have the potential to facilitate the evaluation of cognition in psychosis in both research and in clinical care, though caution should still be taken in terms of implementation and study design.
AB - Despite the functional impact of cognitive deficit in people with psychosis, objective cognitive assessment is not typically part of routine clinical care. This is partly due to the length of traditional assessments and the need for a highly trained administrator. Brief, automated computerised assessments could help to address this issue. We present data from an evaluation of PsyCog, a computerised, non-verbal, mini battery of cognitive tests. Healthy Control (HC) (N = 135), Clinical High Risk (CHR) (N = 233), and First Episode Psychosis (FEP) (N = 301) participants from a multi-centre prospective study were assessed at baseline, 6 months, and 12 months. PsyCog was used to assess cognitive performance at baseline and at up to two follow-up timepoints. Mean total testing time was 35.95 min (SD = 2.87). Relative to HCs, effect sizes of performance impairments were medium to large in FEP patients (composite score G = 1.21, subtest range = 0.52-0.88) and small to medium in CHR patients (composite score G = 0.59, subtest range = 0.18-0.49). Site effects were minimal, and test-retest reliability of the PsyCog composite was good (ICC = 0.82-0.89), though some practice effects and differences in data completion between groups were found. The present implementation of PsyCog shows it to be a useful tool for assessing cognitive function in people with psychosis. Computerised cognitive assessments have the potential to facilitate the evaluation of cognition in psychosis in both research and in clinical care, though caution should still be taken in terms of implementation and study design.
KW - Clinical high risk for psychosis
KW - Cognition
KW - First episode psychosis
KW - Psychosis
UR - http://www.scopus.com/inward/record.url?scp=85188990680&partnerID=8YFLogxK
M3 - Journal article
C2 - 38572271
SN - 2215-0013
VL - 37
SP - 100310
JO - Schizophrenia Research: Cognition
JF - Schizophrenia Research: Cognition
M1 - 100310
ER -